C50.111

Malignant neoplasm of central portion of right female breast

C50.111 is a highly specific 2026 ICD-10-CM code denoting a primary malignancy located within the central portion (subareolar or retroareolar region) of the right breast in a female patient. This anatomical area is complex, containing the terminal lactiferous ducts as they converge toward the nipple. Malignant neoplasms in this location often manifest as invasive ductal carcinoma (IDC) or ductal carcinoma in situ (DCIS), though rarer pathologies like Paget's disease of the breast (when associated with an underlying mass) can also involve this region. Because of its proximity to the nipple-areolar complex, central tumors may result in early visible nipple changes, such as inversion or discharge, but they can also be challenging to palpate if deep within the subareolar tissue. Clinical management involves a multidisciplinary approach including diagnostic imaging (mammography, ultrasound, and potentially MRI), core needle biopsy for histopathological confirmation, and surgical intervention (lumpectomy or mastectomy) followed by possible adjuvant therapies such as radiation, chemotherapy, or hormonal therapy depending on the tumor's molecular subtype (ER/PR and HER2 status).

Clinical Symptoms

Palpable mass located directly behind or adjacent to the right nipple-areolar complex
New-onset retraction or inversion of the right nipple
Spontaneous nipple discharge from the right breast (serous, bloody, or clear)
Skin changes over the central breast including erythema, scaling, or peau d'orange
Persistent itching or crusting of the right nipple (often associated with Paget's disease)
Asymmetry or distortion of the right breast contour in the subareolar region
Unilateral right-sided axillary lymphadenopathy
Localized pain or tenderness in the central breast area (less common in early stages)

Common Causes

Somatic mutations in breast epithelial cells, including PIK3CA and TP53
Germline mutations in high-penetrance susceptibility genes such as BRCA1 and BRCA2
Inherited mutations in moderate-penetrance genes including PALB2, CHEK2, and ATM
Extended lifetime exposure to endogenous estrogen due to early menarche (before age 12) or late menopause (after age 55)
Use of combined estrogen and progestin hormone replacement therapy (HRT)
Increased breast tissue density as seen on screening mammography
Advanced age at first full-term pregnancy or nulliparity
Personal history of atypical hyperplasia or lobular carcinoma in situ (LCIS)
Prior exposure to therapeutic ionizing radiation to the chest area
Modifiable risk factors including obesity, high alcohol consumption, and physical inactivity

Documentation & Coding Tips

Document specific laterality and anatomical sub-site clearly for all breast neoplasms.

Example: Patient presents with a 2.2 cm invasive ductal carcinoma located in the central portion of the right female breast. Clinical staging T2N0M0. Code C50.111 is assigned based on the primary site being the subareolar or central region rather than a specific quadrant.

Billing Focus: Laterality (Right) and sub-site (Central) are essential for C50.111. Failure to specify either results in less specific codes like C50.911 or C50.119 which may trigger payer denials.

Explicitly state the hormone receptor status and HER2/neu status to support complexity.

Example: Patient is a 54-year-old female with malignant neoplasm of the central portion of the right female breast (C50.111). Biopsy confirms Estrogen Receptor positive status (Z17.0) and Progesterone Receptor positive status. HER2/neu is negative. Plan includes targeted endocrine therapy.

Billing Focus: Secondary codes for receptor status (Z17.0, Z17.1) should be used alongside the primary diagnosis to justify medical necessity for specific drug therapies.

Distinguish between primary malignant neoplasm and secondary sites (metastasis) to ensure accurate coding.

Example: Patient diagnosed with malignant neoplasm of central portion of right female breast (C50.111). CT imaging shows secondary malignant neoplasm of the right lung (C78.01) and secondary malignant neoplasm of bone (C79.51).

Billing Focus: Metastatic sites must be coded as secondary neoplasms. Sequencing depends on the reason for the encounter. If treating the primary site, C50.111 is primary.

Capture the current status of the malignancy: active treatment versus history of.

Example: Patient currently receiving adjuvant chemotherapy for malignant neoplasm of the central portion of the right female breast (C50.111). Encounter for chemotherapy session (Z51.11).

Billing Focus: Use C50.111 when the patient is under active treatment (surgery, chemo, radiation). Use Z85.3 (Personal history of malignant neoplasm of breast) only if the primary treatment is completed and there is no evidence of disease.

Identify and document any associated complications such as lymphedema or skin involvement.

Example: Malignant neoplasm of central portion of right female breast (C50.111) with associated postmastectomy lymphedema syndrome (I97.2) of the right upper extremity.

Billing Focus: Complications require separate codes to justify additional procedures or therapeutic interventions (e.g., physical therapy for lymphedema).

Relevant CPT Codes

99205 - Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and high level of medical decision making. When using total time on the date of the encounter for code selection, 60 through 74 minutes of total time is spent on the date of the encounter.
Typically used by oncologists for the initial complex assessment of a new cancer diagnosis including review of pathology and staging.
19307 - Mastectomy, modified radical, including axillary lymphadenectomy, with or without pectoralis minor muscle, but excluding pectoralis major muscle
Standard surgical intervention for invasive central breast cancer.
99214 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and moderate level of medical decision making. When using total time on the date of the encounter for code selection, 30 through 39 minutes of total time is spent on the date of the encounter.
Used for monitoring progress, side effects of chemotherapy, or postoperative healing.
19081 - Biopsy, breast, with placement of localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including stereotactic guidance
Definitive diagnostic procedure to confirm the presence of malignant cells.
96413 - Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
Treatment of active malignancy C50.111.
77263 - Therapeutic radiology treatment planning; complex
Often required following lumpectomy for central breast tumors.
38525 - Biopsy or excision of lymph node(s); open, deep axillary node(s)
Assesses if the central breast cancer has metastasized regionally.
19301 - Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy)
Surgical option for localized central breast tumors.
19281 - Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; first lesion, including mammographic guidance
Necessary to guide the surgeon to the exact central tumor location during surgery.
99213 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and low level of medical decision making. When using total time on the date of the encounter for code selection, 20 through 29 minutes of total time is spent on the date of the encounter.
Appropriate for stable patients on long-term hormonal therapy with no new complications.